| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
213,871,000 |
| Market
Cap: |
2.92(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.3 - $17.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 24.5 |
| Insider 6 Months : 24.5 |
| Insider 3/6 Months : 49 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of of cell therapies as cancer immunotherapy products. Co.'s key product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition, Co. is investigating the effectiveness and safety of tumor infiltrating lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and peripheral blood lymphocyte therapy for treatment of chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,282,000 |
5,282,000 |
10,292,000 |
21,371,500 |
| Total Buy Value |
$48,330,300 |
$48,330,300 |
$74,885,900 |
$147,000,736 |
| Total People Bought |
3 |
3 |
3 |
6 |
| Total Buy Transactions |
3 |
3 |
5 |
18 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fardis Maria |
President and CEO |
• • – |
2020-04-01 |
4 |
D |
$27.94 |
$41,742 |
D/D |
(1,494) |
302,574 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2020-03-02 |
4 |
D |
$35.99 |
$47,543 |
D/D |
(1,321) |
304,068 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2020-02-03 |
4 |
D |
$22.54 |
$29,347 |
D/D |
(1,302) |
305,389 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2020-01-02 |
4 |
D |
$26.68 |
$41,674 |
D/D |
(1,562) |
306,691 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-12-02 |
4 |
D |
$22.66 |
$42,918 |
D/D |
(1,894) |
308,253 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-11-01 |
4 |
D |
$21.97 |
$41,611 |
D/D |
(1,894) |
310,147 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-10-01 |
4 |
D |
$18.21 |
$34,490 |
D/D |
(1,894) |
312,041 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-09-03 |
4 |
D |
$20.27 |
$32,635 |
D/D |
(1,610) |
313,935 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-08-01 |
4 |
D |
$25.17 |
$33,250 |
D/D |
(1,321) |
315,545 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-07-01 |
4 |
D |
$24.62 |
$32,523 |
D/D |
(1,321) |
316,866 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-06-03 |
4 |
D |
$18.04 |
$23,831 |
D/D |
(1,321) |
318,187 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-05-01 |
4 |
D |
$11.14 |
$14,716 |
D/D |
(1,321) |
319,508 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-04-01 |
4 |
D |
$9.78 |
$12,919 |
D/D |
(1,321) |
320,829 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-03-01 |
4 |
D |
$10.77 |
$13,979 |
D/D |
(1,298) |
322,150 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-02-01 |
4 |
D |
$9.26 |
$14,464 |
D/D |
(1,562) |
323,448 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2019-01-02 |
4 |
D |
$9.45 |
$14,761 |
D/D |
(1,562) |
325,010 |
|
- |
|
| Dukes Iain D. |
Director |
– • – |
2018-12-18 |
4 |
B |
$8.65 |
$103,796 |
D/D |
12,000 |
12,000 |
2.39 |
- |
|
| Mcpeak Merrill A |
Director |
– • – |
2018-12-13 |
4 |
B |
$9.63 |
$96,273 |
D/D |
10,000 |
456,583 |
2.39 |
- |
|
| Rothbaum Wayne P. |
Director |
– • – |
2018-12-06 |
4 |
B |
$9.86 |
$2,958,000 |
I/I |
300,000 |
7,067,333 |
2.1 |
- |
|
| Rothbaum Wayne P. |
Director |
– • – |
2018-12-04 |
4 |
B |
$10.31 |
$9,496,056 |
I/I |
921,053 |
6,767,333 |
2.1 |
- |
|
| Fardis Maria |
President and CEO |
• • – |
2018-12-01 |
4 |
D |
$10.44 |
$13,791 |
D/D |
(1,321) |
326,572 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2018-11-01 |
4 |
D |
$9.62 |
$12,708 |
D/D |
(1,321) |
327,893 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2018-10-01 |
4 |
D |
$11.12 |
$14,690 |
D/D |
(1,321) |
329,214 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2018-09-04 |
4 |
D |
$17.10 |
$22,589 |
D/D |
(1,321) |
330,535 |
|
- |
|
| Fardis Maria |
President and CEO |
• • – |
2018-08-01 |
4 |
D |
$13.70 |
$18,098 |
D/D |
(1,321) |
331,856 |
|
- |
|
135 Records found
|
|
Page 4 of 6 |
|
|
0.75 (5.82%) 
